ADC Therapeutics expands to third program with Synaffix

28 May 2019

Dutch biotech firm Synaffix announced that ADC Therapeutics has triggered a third target-specific license under its existing commercial license agreement dated October 2016.

This license provides Switzerland-based ADC Therapeutics with the rights to Synaffix’ proprietary GlycoConnect site-specific antibody-drug conjugation (ADC) and HydraSpace polar spacer technologies to develop and commercialize a third product candidate against a specific target.

Under the terms of the agreement, Synaffix is eligible to receive undisclosed upfront, milestone and royalty payments on a per-target basis. Further financial details were not disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK